1Volm M,Koomagi R,Mattern J,et al.Protein expression profiles indicative for drug resistance of non-small cell lung cancer[J].Br J Cancer,2002,87(2):251-257.
2Dingemans AC,van Ark-Otte J,Span S,et al.TopoisomeraseⅡ alpha and other drug resistance markers in advanced nonsmall cell lung cancer[J].Lung Cancer,2001,32(6):117-128.
3Rintoul RC,Sethi T.The role of extracellular matrix in smallcell lung cancer[J].Lancet Oncol,2001,2(3):437-442.
4Rintoul RC,Sethi T.Extracellular matrix regulation of drugresistance in small-cell lung cancer[J].Clin Sci,2002,102 (4):417-424.
5Shao L,Kasanov J,Homicek FJ.Ecteinascidin-743 drug resistance in sarcoma cells:transcriptional and cellular alterations[J].Biochem Pharmacol,2003,66(5):2381-2395.
6Shain KH,Dalton WS.Cell adhesion is a key determinant in de novo multidrug resistance (MDR):new targets for the prevention of acquired MDR[ J ].Molecular Cancer Therapeutics,2001,1(1):69-78.
7Nakanishi Y,Kawasaki M,Bai F,et al.Expression of p53and glutathione S-transferase-pi relates to clinical drug resistance in non-small cell lung cancer[J].Oncology,1999,57(6):318-323.
8Kawai H,Kiura K,Tabata M,et al.Characterization of nonsmall-cell lung cancer cell lines established before and after chemotherapy[J].Lung Cancer,2002,35(2):305-314.
9Vogt U,Zaczek A,Klinke F,et al.p53 gene status in relation to exvivo chemosensitivity of non-small cell lung cancer.J Cancer[J].Res Clin Oncol,2002,128(5):141-147.
10Sartorius UA,Krammer PH.Upregulation of Bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines[J].Int J Cancer,2002,97 (1):584-592.
